
About this episode
As biomedical data proliferates and the life sciences becomes more closely integrated with data science, the ability for researchers to access, use, and learn from the growing universe of information requires new tools. InveniAI is seeking to address this need with its artificial intelligence platform for biopharmaceutical companies to both monitor innovation and to enhance their own drug development capabilities. We spoke to Krishnan Nandabalan, president and CEO of InveniAI, about the company, how its artificial intelligence platform is being used, and what he expects the ultimate payoff from this technology will be.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report

Resetting Severe Allergies at Their Cellular Source
The Bio Report
Sep 2, 202633:17pending

Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report
Aug 26, 202629:35pending

Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report
Aug 19, 202634:19pending

How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report
Aug 12, 202638:31pending